AIM Vaccine

AIM Vaccine is a large private vaccine group in China with a full industry chain, covering the entire industry value chain from research and development to manufacturing and commercialization. In 2020, it achieved a batch release volume of approximately 60 million doses and successfully sold its vaccine products to all 31 provinces, autonomous regions, and municipalities across China. AIM Vaccine owns five proven human vaccine platform technologies, which greatly ensure the company's R&D speed and flexibility. Currently, the company has eight commercialized vaccines targeting six disease areas and 22 innovative vaccines under development for 13 disease areas. Its commercialized and in-development products cover all top ten vaccine products globally (based on global sales in 2020).Through a decade of development, the company has formed an inclusive and pioneering business model and corporate culture, allowing it to continuously expand and optimize its existing operations. The company fully owns four licensed vaccine production enterprises: AIM Integrity, AIM Kanghuai, AIM Weixin, and Rong'an Biotech. It also holds stakes in three research institutes, including the R&D center established in 2018—AIM Explorer—which focuses on providing technical support for early-stage and cutting-edge research in the R&D departments of various factories. In 2021, AIM acquired Zhuhai Lifanmao Biotechnology Co., Ltd., one of the three earliest companies in China to receive clinical trial approval for an mRNA COVID-19 vaccine, possessing an independent mRNA production and drug delivery technology platform.AIM Vaccine Group always adheres to the mission of "Producing Conscientious Vaccines, Promoting Global Health" and strictly controls vaccine quality. The company has a professional and dedicated sales team comprising over 100 members with an average of more than 10 years of experience in pharmaceutical or vaccine sales. The core commercial leadership team averages 12 years of experience in vaccine commercialization at multinational pharmaceutical companies and has an outstanding track record in marketing globally significant vaccines (including the world’s first HPV, IPV, and DTaP-IPV-Hib vaccines). Currently available products include Recombinant Hepatitis B Vaccine (Hansenula polymorpha), Freeze-dried Human Rabies Vaccine (Vero cells), Inactivated Hepatitis A Vaccine (Human Diploid Cells), Mumps Attenuated Live Vaccine, Bivalent Hemorrhagic Fever with Renal Syndrome Inactivated Vaccine (Vero cells), and Meningococcal Polysaccharide Vaccine Group A, C, Y, and W-135 (MPSV4).